Epratuzumab for Systemic Lupus Erythematosus

被引：22
作者：
Wallace, D. J. [1 ]
Goldenberg, D. M. [2 ,3 ]
机构：
[1] Univ Calif Los Angeles, Cedars Sinai David Geffen Sch Med, Los Angeles, CA USA
[2] Ctr Mol Med & Immunol, Morris Plains, NJ USA
[3] Immunomedics Inc, Morris Plains, NJ USA
来源：
LUPUS | 2013年 / 22卷 / 04期
关键词：
B cells; BILAG; CD22; epratuzumab; immunotherapy; systemic lupus erythematosus; HUMANIZED ANTI-CD22 ANTIBODY; B-CELLS; MONOCLONAL-ANTIBODY; CD22; RECEPTOR; THERAPY; ANTIGEN; EXPRESSION;
D O I：
10.1177/0961203312469692
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). An overview of its mechanism of action is followed by a summary of completed lupus studies, and a preview of studies in progress. The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders. Lupus (2013) 22, 400-405.
引用
收藏
页码：400 / 405
页数：6
相关论文
共 34 条
  • [1] Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
    Aletaha, D.
    Strand, V.
    Smolen, J. S.
    Ward, M. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 238 - 243
  • [2] Carnahan J, 2003, CLIN CANCER RES, V9, p3982S
  • [3] Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
    Carnahan, Josette
    Stein, Rhona
    Qu, Zhengxing
    Hess, Kristen
    Cesano, Alessandra
    Hansen, Hans J.
    Goldenberg, David M.
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (06) : 1331 - 1341
  • [4] CHAOUCHI N, 1995, J IMMUNOL, V154, P3096
  • [5] Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
    Daridon, Capucine
    Blassfeld, Daniela
    Reiter, Karin
    Mei, Henrik E.
    Giesecke, Claudia
    Goldenberg, David M.
    Hansen, Arne
    Hostmann, Arwed
    Froelich, Daniela
    Doerner, Thomas
    [J]. ARTHRITIS RESEARCH & THERAPY, 2010, 12 (06)
  • [6] Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
    Doerner, Thomas
    Kaufmann, Joerg
    Wegener, William A.
    Teoh, Nick
    Goldenberg, David M.
    Burmester, Gerd R.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2006, 8 (03)
  • [7] CD22 and Autoimmune Disease
    Doerner, Thomas
    Shock, Anthony
    Smith, Kenneth G. C.
    [J]. INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2012, 31 (05) : 363 - 378
  • [8] B cells in autoimmunity
    Doerner, Thomas
    Jacobi, Annett M.
    Lipsky, Peter E.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
  • [9] A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP
    DOODY, GM
    JUSTEMENT, LB
    DELIBRIAS, CC
    MATTHEWS, RJ
    LIN, JJ
    THOMAS, ML
    FEARON, DT
    [J]. SCIENCE, 1995, 269 (5221) : 242 - 244
  • [10] DORKEN B, 1986, J IMMUNOL, V136, P4470
1234